Skip To Main Content
LUCENTIS Biosimilar on Muck Rack

LUCENTIS Biosimilar

As seen in: TechDogs
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with LUCENTIS

Contact LUCENTIS, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

BostonGene Named To The 2023 CB Insights' Digital Health 50 List

|
By BioTechnologySQI Diagnostics, BioTechnologyGC Cell, LUCENTIS Biosimilar, BioTechnologyBIO Partnering
| TechDogs
BioTechnology BostonGene’s innovative solutions and deep expertise in AI-based molecular and immune profiling recognized as a leader in diagnosis and imaging, propelling precision medicine for patients with cancer and other immune-related diseases WALTHAM, Mass.--(BUSINESS WIRE)--CB Insights named BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, to its fifth-annual Digital Health 50 showcasing the 50 most promising private digital health companies of 2023.
Open in Who Shared Issue with article?

BioStrand Unveils A Revolutionary Approach To Biological Sequence Retrieval: A Fusion Of Natural Language Processing And Database Research

|
By BioTechnologySQI Diagnostics, BioTechnologyGC Cell, LUCENTIS Biosimilar
| TechDogs
VICTORIA, British Columbia--(BUSINESS WIRE)--$IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is thrilled to announce that its subsidiary, BioStrand®, has published a preprint of its groundbreaking white paper titled, "New Paradigm for Biological Sequence Retrieval Inspired by Natural Language Processing and Database Research" on bioRχiv.
Open in Who Shared View Duplicates (34) Issue with article?

Tevogen Bio Introduces Tevogen.ai To Enhance Patient Accessibility And Accelerate Innovation Leveraging Artificial Intelligence

|
By BioTechnologySQI Diagnostics, BioTechnologyGC Cell, LUCENTIS Biosimilar
| TechDogs
WARREN, N.J.--(BUSINESS WIRE)--#COVID19--Tevogen Bio Inc (“Tevogen Bio”) announces the inception of Tevogen.ai, a new initiative focused on harnessing the potential of artificial intelligence (AI) for the enhancement of drug discovery, development, manufacturing, distribution, and patient access.
Open in Who Shared View Duplicates (51) Issue with article?
See all 5 articles